Comparative studies on the distribution and metabolic fate of diphenylhydantoin and 3-ethoxycarbonyldiphenylhydantoin (P-6127) after chronic administrations to dogs and cats
- 10 Downloads
The oral administration of 100 mg/kg/day of DPH or P-6127 to dogs and cats for more than 1 year resulted in preferential accumulations of the drugs in the superior and inferior colliculus, amygdala, and hippocampus compared to 16 other cerebral areas examined without any manifestation of neurotoxicity. The relative brain to blood levels of DPH in the animals were higher than those of epileptic patients on a maintenance dose.
Both drugs were found concentrated in the pituitary and adrenal; P-6127 less so than DPH. This may be the cause of the infrequent gingival hyperplasia or hirsutism.
DPH was metabolized to the pharmacologically inactive HPPH and a trace of inactive DPHA was found in the chronically treated animals. The ethoxycarbonyl group of P-6127 was split off to form DPH.
The brain/blood and brain/cerebrospinal fluid concentration ratios were higher for P-6127 than for DPH. This may explain the greater anticonvulsant activity of P-6127 in the animals.
KeywordsOral Administration Diphenylhydantoin Blood Level Concentration Ratio Maintenance Dose
Unable to display preview. Download preview PDF.
- Bernheim, F.: The hydrolysis of hydantoin by various tissues. Fed. Proc. 6, 238–239 (1947).Google Scholar
- ——, and M. L. C. Bernheim: The specificity of hydantoinase. J. biol. Chem. 163, 683–685 (1946).Google Scholar
- Butler, T. C.: The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenyl hydantoin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 119, 1–11 (1957).Google Scholar
- ——, and W. J. Waddell: The metabolic fate of 5-ethyl-1-methyl-5-phenyl hydantoin (1-methylnirvanol) and that of 3,5-diethyl-5-phenyl hydantoin (3-ethylnirvanol). Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 127, 171–174 (1959).Google Scholar
- Dill, W. A., A. Kazenko, L. M. Wolf, and A. J. Glazko: Studies on 5,5-diphenylhydantoin (Dilantin) in animals and man. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 118, 270–279 (1956).Google Scholar
- Gorvin, J. H., and G. Brownlee: Metabolism of 5,5-diphenylhydantoin in the rabbit. Nature (Lond.) 179, 1248 (1957).Google Scholar
- Jasper, H. H., and C. Ajmone-Marsan: A stereotaxic atlas of the diencephalon of the cat. Ottawa: National Research Council of Canada 1954.Google Scholar
- Kozelka, F., and C. H. Hine: Degradation products of Dilantin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 77, 175–179 (1943).Google Scholar
- Kishi, Y., S. Manmaru, S. Fukui, and K. Aoki: Treatment of epilepsy with 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127), a new anticonvulsive agent. Brain and Nerve 16, 982–993 (1964).Google Scholar
- Krieger, D. T.: Effect of diphenylhydantoin on pituitaryadrenal interrelations. J. clin. Endocr. 22, 490–493 (1962).Google Scholar
- Kutt, H., W. Winters, R. Kokenge, and F. McDowell: Diphenylhydantoin metabolism, blood levels, and toxicity. Arch. Neurol. (Chic.) 11, 642–648 (1964).Google Scholar
- Lim, R. K. S., and C. Liu: A stereotaxic atlas of the dog's brain. Springfield, Ill.: Ch. C. Thomas 1960.Google Scholar
- Loeser, E. W., jr.: Studies on the metabolism of diphenylhydantoin (Dilantin). Neurology (Minneap.) 11, 424–429 (1961).Google Scholar
- Maynert, E. W.: The metabolic fate of diphenylhydantoin in the dog, rat, and man. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 130, 275–284 (1960).Google Scholar
- Merrit, H. H., and T. J. Putnam: Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J. Amer. med. Ass. 111, 1068–1073 (1938).Google Scholar
- Nakamura, K., K. O'Hashi, K. Nakatsuji, T. Hirooka, K. Fujimoto, and S. Ose: The anticonvulsant activity of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) in animals. Arch. int. Pharmacodyn. 156, 261–270 (1965).Google Scholar
- ——, and M. Kurebe: Differential effects of antiepileptics on hippocampal and pallidal afterdischarges in cats. Jap. J. Pharmacol. 12, 180–190 (1962).Google Scholar
- --, and Y. Masuda: Effects of 5,5-diphenylhydantoin and 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) on the dermal and gingival tissues of the experimental animals. Arch. int. Pharmacodyn. (in press) (1966).Google Scholar
- Noach, E. L., D. M. Woodbury, and L. S. Goodman: Studies on the absorption, distribution, fate, and excretion of 4-C14-labelled diphenylhydantoin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 122, 301–314 (1958).Google Scholar
- Quinn, D. L.: Influence of diphenylhydantoin on spontaneous release of ovulating hormone in the adult rat. Proc. Soc. exp. Biol. (N. Y.) 119, 892–985 (1965).Google Scholar
- Rosenblum, I., and A. A. Stein: Preferential distribution of diphenylhydantoin in primary human brain tumors. Biochem. Pharmacol. 12, 1453–1454 (1963).Google Scholar
- Snider, R. S., and W. T. Niemer: A stereotaxic atlas of the cat brain. Chicago: University of Chicago Press 1961.Google Scholar
- Swinyard, E. A., W. C. Brown, and L. S. Goodman: Comparative assays of antiepileptic drugs in mice and rats. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 106, 319–330 (1952).Google Scholar
- Taen, S., Y. Goto, K. Sekiba, and S. Arai: On the antiepileptic activities of a new compound, ethoxycarbonyldiphenylhydantoin. Brain and Nerve 16, 977–981 (1964).Google Scholar
- Toman, J. E. P., E. A. Swinyard, and L. S. Goodman: Properties of maximal seizures, and their alteration by anticonvulsant drugs and other agents. J. Neurophysiol. 9, 231–239 (1946).Google Scholar
- Woodbury, D. M.: Effect of hormones on brain excitability and electrolytes. Recent Advanc. Hormone Res. 10, 65–101 (1954).Google Scholar
- —— P. S. Timiras, and A. Vernadakis: Hormone, brain, function and behavior, pp. 27–50. New York: Academic Press 1957.Google Scholar